Notice ID: 43994770ad1f4ecea6de70df9c7c9ff9Combined Synopsis/Solicitation
Sedia Biosciences Corporation Assays - Notice of Intent for Sole Source Award
Archived on September 5, 2023. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM UTC−04:00
- Posted
- August 31, 2023
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 325413: In-Vitro Diagnostic Substance Manufacturing
- Agency
- Department of Health and Human ServicesCENTERS FOR DISEASE CONTROL AND PREVENTION
Notice details
- Office
- CDC OFFICE OF ACQUISITION SERVICES
- Place of performance
- Atlanta, GA, 30329
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75D301-20-Q-72405
- Notice ID
- 43994770ad1f4ecea6de70df9c7c9ff9
Description
The Centers for Disease Control and Prevention intends to award a sole source firm fixed price purchase order to Sedia Biosciences Corporation of Portland, OR, for Asante HIV-1 Rapid Recency Assays and HIV-1 LAg-Avidity EIA Avidity Kits. The assays and kits required are provided only by this company and are used in an ongoing HIV surveillance program. This contract action is for supplies for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) (SAP) and 10 U.S.C. 2304(c)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations. Any interested companies are welcome to submit their ability to provide the specified products within three (3) days of the issuance of this notice. A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to contract specialist at emickle@cdc.gov by COB after three (3) business days from date of posting.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75D301-20-Q-72405- Combined Synopsis
- Combined SynopsisCurrentAug 31, 2023
Sedia Biosciences Corporation Assays - Notice of Intent for Sole Source Award
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information. | - | Solicitation | 02/15/2026 |
Please see attached Combined Synopsis/Solicitation. See attached estimated quantities and Questions and Answers. | - | Combined Synopsis | 11/18/2026 |
See attached Sources Sought Notice. | - | Market Research | 10/28/2026 |
(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested, and a separate written solicitation will not be issued. (ii) The solicitation number is 75N98027Q00027. This solicitation is issued as a Notice of Intent (NOI) for a non-competitive combined synopsis/solicitation to award a contract or purchase order without providing for full and open competition (including brand-name, if applicable). This acquisition is conducted under the authority of FAR 12.603, Streamlined Solicitation for Commercial Products or Commercial Services, and is not expected to exceed the simplified acquisition threshold. Additional authority includes 41 U.S.C. 1901 and FAR 6.302-3(a)(2)(ii). The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, intends to negotiate and award a firm-fixed-price purchase order on a non-competitive basis to Integrated DNA Technologies, Inc. (IDT), 1710 Commercial Park, Coralville, IA 52241, for custom-designed ArcherDX VariantPlex Next-Generation Sequencing (NGS) target-enrichment library preparation kits. Integrated DNA Technologies, Inc. is the sole owner, manufacturer, and distributor of the proprietary ArcherDX VariantPlex Anchored Multiplex PCR (AMP) chemistry, which has been utilized by the NHLBI Hematology Branch since 2019 to perform error-correcting sequencing (ECS) and is required to maintain scientific continuity, prevent technical batch effects across longitudinal patient cohorts, and ensure compatibility with the laboratory¿s established Archer Analysis bioinformatics pipeline. All responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. (iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2026-01, effective 03/13/2026. (iv) The associated NAICS code is 325413 (In-Vitro Diagnostic Substance Manufacturing) and the small business size standard is 1,250 employees. This requirement is not set aside for small business. | - | Combined Synopsis | 11/05/2026 |
See attached Notice of Intent to Sole Source HT941027N0010 | - | Special Notice | 11/23/2026 |
Additional Details
Solicitation Number
75D301-20-Q-72405
Archive Date
Sep 5, 2023
Office Address
ATLANTA, GA, 30333